Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanza triple) program for cystic fibrosis ...

tezacaftor and ivacaftor. Vertex said the positive results were even more pronounced in a study of the vanza triple in children aged six to 11, “demonstrating the potential that treating early ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

The next phase of Vertex is focused on the roll-out of its new triple Kaftrio (tezacaftor, ivacaftor and elexacaftor), which was launched last year in the US (as Trikafta) and was approved by the ...

Please provide your email address to receive an email when new articles are posted on . Researchers deemed 24-week vanzacaftor/tezacaftor/deutivacaftor safe in 6- to ...

Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

Vanzacaftor-tezacaftor-deutivacaftor, a novel therapeutic, once-daily drug, demonstrates noninferiority to elexacaftor-tezacaftor-ivacaftor (the twice-daily, standard-of-care drug) in lung ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...